Controversies around epithelial–mesenchymal plasticity in cancer metastasis
ED Williams, D Gao, A Redfern… - Nature Reviews Cancer, 2019 - nature.com
Experimental evidence accumulated over decades has implicated epithelial–mesenchymal
plasticity (EMP), which collectively encompasses epithelial–mesenchymal transition and the …
plasticity (EMP), which collectively encompasses epithelial–mesenchymal transition and the …
Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature
RN Pillai, M Behera, TK Owonikoko, AO Kamphorst… - Cancer, 2018 - Wiley Online Library
BACKGROUND Monoclonal antibodies against programmed cell death protein 1 (PD‐1)
and programmed death ligand 1 (PD‐L1) are effective therapies in patients with non‐small …
and programmed death ligand 1 (PD‐L1) are effective therapies in patients with non‐small …
Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers
K Pawelczyk, A Piotrowska, U Ciesielska… - International journal of …, 2019 - mdpi.com
Background: The latest immunotherapy, used in the treatment of non-small cell lung cancer
(NSCLC), uses monoclonal antibodies directed against programmed death ligand 1 (PD-L1) …
(NSCLC), uses monoclonal antibodies directed against programmed death ligand 1 (PD-L1) …
PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis
M Zhang, G Li, Y Wang, Y Wang, S Zhao, P Haihong… - Scientific reports, 2017 - nature.com
Although many studies have addressed the prognostic value of programmed cell death-
ligand 1 (PD-L1) expression in lung cancer, the results remain controversial. A systematic …
ligand 1 (PD-L1) expression in lung cancer, the results remain controversial. A systematic …
PLK1/vimentin signaling facilitates immune escape by recruiting Smad2/3 to PD-L1 promoter in metastatic lung adenocarcinoma
HR Jang, SB Shin, CH Kim, JY Won, R Xu… - Cell Death & …, 2021 - nature.com
The prerequisite function of vimentin for the epithelial–mesenchymal transition (EMT) is not
clearly elucidated yet. Here, we show that vimentin phosphorylated by PLK1, triggers TGF-β …
clearly elucidated yet. Here, we show that vimentin phosphorylated by PLK1, triggers TGF-β …
A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
JM David, C Dominguez, KK McCampbell… - …, 2017 - Taylor & Francis
Mesenchymalization is a cellular and molecular program in which epithelial cells
progressively lose their well-differentiated phenotype and adopt mesenchymal …
progressively lose their well-differentiated phenotype and adopt mesenchymal …
PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer
R Okita, A Maeda, K Shimizu, Y Nojima… - Cancer Immunology …, 2017 - Springer
Immunocheckpoint inhibitors targeting the programmed cell death-1 (PD-1) and PD-1 ligand
1 (PD-L1) axis have shown promising results in patients with non-small-cell lung cancer …
1 (PD-L1) axis have shown promising results in patients with non-small-cell lung cancer …
[HTML][HTML] Radiomics study for predicting the expression of PD-L1 and tumor mutation burden in non-small cell lung cancer based on CT images and clinicopathological …
Q Wen, Z Yang, H Dai, A Feng, Q Li - Frontiers in oncology, 2021 - frontiersin.org
Background The present study compared the predictive performance of pretreatment
computed tomography (CT)-based radiomics signatures and clinicopathological and CT …
computed tomography (CT)-based radiomics signatures and clinicopathological and CT …
EBUS-TBNA as a promising method for the evaluation of tumor PD-L1 expression in lung cancer
R Sakakibara, K Inamura, Y Tambo, H Ninomiya… - Clinical lung cancer, 2017 - Elsevier
Background Because most lung cancers are diagnosed at advanced stages, we are forced
to conduct molecular testing using small biopsy samples. Endobronchial ultrasound …
to conduct molecular testing using small biopsy samples. Endobronchial ultrasound …
[HTML][HTML] Programmed cell death ligand (PD-L1) expression in stage II and III lung adenocarcinomas and nodal metastases
H Uruga, E Bozkurtlar, TG Huynh, A Muzikansky… - Journal of Thoracic …, 2017 - Elsevier
Introduction Programmed death ligand 1 (PD-L1) expression determined by
immunohistochemistry (IHC) may serve as a predictive biomarker for anti–PD-1/PD-L1 …
immunohistochemistry (IHC) may serve as a predictive biomarker for anti–PD-1/PD-L1 …